KV Pharmaceutical’s quick slide from the top

Par Pharmaceutical Enters Into Agreement With sanofi-aventis to Settle Patent Litigation Over Generic Eloxatin(R) Par Pharmaceutical Companies, Inc. (NYSE: PRX) today announced that it (and its subsidiary Par Pharmaceutical and development partner MN Pharmaceuticals of Turkey) has entered into a settlement agreement with sanofi-aventis (sanofi) that resolves patent litigation related to its generic version of sanofi’s and Debiopharm’s Eloxatin(®) Read more on redOrbit

Par Pharmaceutical Enters Into Agreement With sanofi-aventis to Settle Patent Litigation Over Generic Eloxatin(R) Par Pharmaceutical Companies, Inc. today announced that it has entered into a settlement agreement with sanofi-aventis that resolves patent litigation related to its generic version of sanofi’s and Debiopharm’s Eloxatin® product, a drug used to treat colorectal cancer, in the U.S. Read more on PR Newswire via Yahoo! Finance

Roxbury attorney is named âRising Starâ ROXBURY TWP. — Roxbury resident and Lowenstein Sandler PC attorney, Vincent A. Antoniello, has been selected for inclusion in the 2010 edition of “New Jersey Rising Stars,” which recognizes the state’s top up-and-coming attorneys. Read more on Roxbury Register

KV Pharmaceutical’s quick slide from the top Not long ago, drug manufacturer KV Pharmaceutical Co. was a rising star in the health care industry. A maker of women’s health products and scores of generic drugs, KV had dozens of patents and a growing platform for a variety of medicines — from powerful painkillers to children’s cough syrups. Read more on St. Louis Post-Dispatch